A Phase IV Multicenter Trial to Evaluate Real-world Health Outcomes, Economic Impact and Resistance Mechanisms of Panitumumab in the Treatment of Patients With Chemotherapy-refractory Metastatic Colorectal Cancer
Phase of Trial: Phase IV
Latest Information Update: 02 Apr 2018
Price : $35 *
At a glance
- Drugs Panitumumab (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- Sponsors PeriPharm
- 29 Mar 2018 Status changed from active, no longer recruiting to completed.
- 13 Jan 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 22 Aug 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov